Search the Newsreel

TransMedics Group (TMDX) Stock Faces Margin Pressure After Record Revenue

Insmed (INSM) Is Up 30.6% After Steeply Narrowing Losses And Raising 2026 Revenue Guidance – What’s Changed

Insmed (NASDAQ:INSM) Shares Gap Up After Better-Than-Expected Earnings

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Insmed (INSM) Earnings Date and Reports 2026

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Q2 2026 Transmedics Group Inc Earnings Call Transcript

TransMedics Group Inc (TMDX) reported strong Q2 2026 revenue of ~$190 million, up 21% year-over-year, driven by significant growth in service revenue and logistics market share gains. The company raised its full-year revenue guidance while acknowledging a decline in adjusted operating margin due to …

Morgan Stanley Maintains Allison Transmission(ALSN.US) With Hold Rating, Raises Target Price to $132

Morgan Stanley has reiterated its "Hold" rating for Allison Transmission (ALSN.US) while simultaneously increasing its price target to $132. This indicates a maintained neutral stance on the stock but with a higher expected valuation.

Insmed Number of Employees 2026 | Employee Count & Headcount Data

Insmed, Inc. (NASDAQ: INSM) had approximately 1,713 employees worldwide as of March 2026, marking a 76.1% growth from 2023. The company is actively hiring, with 192 job postings in 2026, a 32.0% increase from 2025. Insmed's workforce is concentrated in North America, and the …

TransMedics Group, Inc. Stock 12‑Month Price Target Cut to $97.3, Implies 20% Upside

Analysts have cut the 12-month average price target for TransMedics Group, Inc. (TMDX) stock from $106 to $97.3, which still suggests a 20% upside based on its closing price on August 4th. The consensus rating from 12 analysts remains a "Buy," with 8 recommending …

Allison Transmission (ALSN) Stock Rallies Behind Record Cash And Bigger Scale

Allison Transmission Holdings (ALSN) saw its stock rally 5.6% after a significant Q2 2026 report, highlighted by net sales of US$1.566 billion following the Off Highway acquisition, and record adjusted free cash flow of US$281 million. The company is transitioning into a larger, higher-margin …

TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract

TransMedics (TMDX) reported a Q2 2026 earnings per share miss of 44 cents, a 52.2% year-over-year decrease, despite revenues rising 20.7% to $189.9 million, surpassing estimates. The company's gross margin contracted, and operating expenses significantly increased due to investments in clinical programs and product …

Allison Transmission Holdings Inc Q2 2026: Revenue $1.57B, EPS $2.15— 10-Q Summary

Allison Transmission Holdings Inc (ALSN) reported its Q2 2026 results, showing a significant increase in revenue to $1.57 billion, up 92% year-over-year, primarily due to a January acquisition. Despite the revenue growth, net income and diluted EPS saw slight declines compared to the prior-year …

UBS Adjusts Price Target on TransMedics Group to $77 From $80, Maintains Neutral Rating

UBS has revised its price target for TransMedics Group (TMDX) down to $77 from $80, while maintaining a "Neutral" rating on the stock. This adjustment comes after the company reported its Q2 2026 earnings, where adjusted net income fell despite a rise in revenue. …

InvestingPro’s fair value predicted Insmed’s 45% decline 8 months early By Investing.com

InvestingPro's Fair Value analysis accurately predicted a significant decline in Insmed (NASDAQ:INSM) shares, flagging a 38.5% overvaluation eight months before the stock plummeted 44.66%. The analysis, which combines multiple sophisticated valuation methodologies, indicated the biopharmaceutical company's intrinsic worth was significantly lower than its trading …

TransMedics Group (TMDX) Stock Rises on Q2 2026 Earnings

TransMedics Group (TMDX) reported Q2 2026 revenue of $189.9 million, exceeding estimates, which led to a 9.62% rise in share price after market close. Despite revenue growth, profitability decreased, with operating profit down 35.1% and net income down 57.9%. The article also details recent …

Why TransMedics Stock Is Sinking Today

Shares of leading, next-gen organ transplant systems specialist TransMedics (NASDAQ: TMDX) are down 8% as of 1 p.m. ET Wednesday after the company reported underwhelming second-quarter earnings. Sales growth of 21% beat analysts' hopes, but adjusted net income was more than halved, falling short …

TRANSMEDICS GROUP, INC. : CANACCARD GENUITY CUTS TARGET PRICE TO $95 FROM $124

Canaccord Genuity has reduced its target price for TransMedics Group, Inc. (TMDX.O) from $124 to $95. This information was reported by Reuters on August 5, 2026. The article advises readers that its content reflects only the author's opinion and should not be used as …

TransMedics Group (TMDX) Stock Looks Cheap On Earnings But Full After 171% Gain

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. TransMedics Group stock has delivered a 170.9% gain over the past five years, yet …

TransMedics Group Q2 Earnings Call Highlights

TransMedics Group reported record Q2 revenue of $190 million, up 21% year over year, driven by strong liver and logistics growth. Despite this, the company lowered its full-year adjusted operating margin outlook to 12.5%-14% due to significant investments in heart and lung adoption, OCS …

TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Expectations By $0.06 EPS

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings, reporting $0.44 EPS, which missed analyst expectations by $0.06, despite revenue of $189.95 million exceeding estimates. The company's shares fell 1.0% to $80.75 following the announcement. Analysts have a mixed view, with an average "Hold" rating and …

TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, TransMedics (TMDX) reported revenue of $189.95 million, up 20.7% over the same period last year. EPS came in at $0.44, compared to $0.92 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $184.17 …

TransMedics (TMDX) Q2 Earnings Lag Estimates

TransMedics (TMDX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

TransMedics Group, Inc. Quarterly Earnings Report

TransMedics Group, Inc. Q2 2026: Revenue $189.9M, EPS $0.41— 10-Q Summary

TransMedics Group, Inc. reported its Q2 2026 financial results, showing revenue of $189.9 million, a 20.7% increase year-over-year, primarily driven by OCS Liver sales and NOP service usage. Despite revenue growth, net income declined by 57.9% to $14.7 million, resulting in a diluted EPS …

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Group, Inc. announced strong financial results for the second quarter of 2026, with total revenue reaching $189.9 million, a 21% increase year-over-year. The company reported a net income of $14.7 million ($0.41 per diluted share) and raised the low end of its full-year …

TransMedics Group (TMDX) Nears Earnings, Where Does Fair Value Sit?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TransMedics Group (TMDX) heads into a busy early August, with Q2 2026 results and an earnings call scheduled for August 4 after the …

Do TransMedics’ (TMDX) New Equity Grants And UBS Coverage Reveal A Shifting Growth Playbook?

TransMedics Group (TMDX) announced Q2 2026 financial results, new equity grants to employees, and received fresh UBS research coverage with an $80 price target and Neutral rating. These developments suggest a shifting focus towards internal talent incentives and external analyst attention as the company …

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased TransMedics Group, Inc. (TMDX) securities prior to February 3, 2022, and continue to hold them. The investigation seeks to determine if TransMedics and its officers engaged in corporate wrongdoing. …

TransMedics Group, Inc. $TMDX Shares Bought by First Trust Advisors LP

First Trust Advisors LP significantly increased its stake in TransMedics Group, Inc. by 111.5% in the first quarter, now owning 53,889 shares valued at $5,357,000. Several other institutional investors also expanded their positions, bringing total institutional and hedge fund ownership to 99.67%. Despite this …

Here's What Key Metrics Tell Us About Allison Transmission (ALSN) Q2 Earnings

For the quarter ended June 2026, Allison Transmission (ALSN) reported revenue of $1.57 billion, up 92.4% over the same period last year. EPS came in at $2.73, compared to $2.29 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Allison Transmission Q2 Earnings Call Highlights

Allison Transmission reported strong Q2 2026 results with net sales up 92% to $1.566 billion, driven by the addition of its Off-Highway business and growth in legacy transmission operations. The company raised its full-year outlook, citing improving market conditions and record adjusted free cash …

Allison Transmission (ALSN) Surpasses Q2 Earnings and Revenue Estimates

Allison Transmission (ALSN) came out with quarterly earnings of $2.73 per share, beating the Zacks Consensus Estimate of $2.6 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Allison Transmission (NYSE:ALSN) Posts Better-Than-Expected Sales In Q2 CY2026, Full-Year Sales Guidance is Optimistic

Allison Transmission (NYSE:ALSN) Posts Better-Than-Expected Sales In Q2 CY2026, Full-Year Sales Guidance is Optimistic Transmission provider Allison Transmission (NYSE:ALSN) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 92.4% year on year to $1.57 billion. The company's full-year revenue guidance …

Allison Transmission Holdings (ALSN) Releases Q2 2026 Earnings: Revenue Jumps 92% but EPS Declines

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. announced the grant of non-qualified stock options and restricted stock units to nine new employees as a material inducement for their employment. These grants, totaling 18,762 shares in stock options and 12,414 restricted stock units, were approved by the Compensation Committee …